Jazz Pharmaceuticals shared a post on LinkedIn:
“We recognize the complexities of HER2 cancers, which is why we’ve placed a strategic focus on HER2 development to help address the ongoing unmet needs faced by patients and their families.
Global Head of R/D and Chief Medical Officer Robert Iannone sat down with Fierce Pharma to discuss the evolving landscape of HER2-targeted agents in cancer care and how we’re continuing to build our HER2 platform to drive long-term impact for patients and their families. Watch the full interview to learn more.”
Other articles about Jazz Pharmaceuticals on OncoDaily.